- $34.07bn
- $33.26bn
- $5.65bn
Annual cashflow statement for ResMed, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 779 | 898 | 1,021 | 1,401 | 1,523 |
| Depreciation | |||||
| Non-Cash Items | 120 | 92.7 | 159 | 136 | 155 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -708 | -462 | 44.8 | 16.7 | -74.2 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | 351 | 693 | 1,401 | 1,752 | 1,806 |
| Capital Expenditures | -156 | -134 | -115 | -101 | -177 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -73.9 | -1,026 | -155 | -99.4 | -368 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -230 | -1,160 | -270 | -200 | -545 |
| Financing Cash Flow Items | -52.4 | -33 | -10.1 | -29.8 | -21.8 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -128 | 423 | -1,119 | -606 | -1,007 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -21.6 | -45.8 | 10.5 | 971 | 260 |